130 related articles for article (PubMed ID: 11883695)
1. Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer.
Rees RC; McArdle S; Mian S; Li G; Ahmad M; Parkinson R; Ali SA
Curr Opin Mol Ther; 2002 Feb; 4(1):49-53. PubMed ID: 11883695
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
3. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
4. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer.
Todryk S; McLean C; Ali S; Entwistle C; Boursnell M; Rees R; Vile R
Hum Gene Ther; 1999 Nov; 10(17):2757-68. PubMed ID: 10584922
[TBL] [Abstract][Full Text] [Related]
5. Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production.
Karpoff HM; Kooby D; D'Angelica M; Mack J; Presky DH; Brownlee MD; Federoff H; Fong Y
Cancer Gene Ther; 2000 Apr; 7(4):581-8. PubMed ID: 10811476
[TBL] [Abstract][Full Text] [Related]
6. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
7. Replication-competent herpes simplex vectors: design and applications.
Argnani R; Lufino M; Manservigi M; Manservigi R
Gene Ther; 2005 Oct; 12 Suppl 1():S170-7. PubMed ID: 16231051
[TBL] [Abstract][Full Text] [Related]
8. [Herpes simplex virus vaccine studies: from past to present].
Us D
Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
11. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
12. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer with herpes simplex vectors.
Lachmann RH; Efstathiou S
Curr Opin Mol Ther; 1999 Oct; 1(5):622-32. PubMed ID: 11249669
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour therapeutic efficacy of OX40L in murine tumour model.
Ali SA; Ahmad M; Lynam J; McLean CS; Entwisle C; Loudon P; Choolun E; McArdle SE; Li G; Mian S; Rees RC
Vaccine; 2004 Sep; 22(27-28):3585-94. PubMed ID: 15315837
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
17. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.
Ali SA; Lynam J; McLean CS; Entwisle C; Loudon P; Rojas JM; McArdle SE; Li G; Mian S; Rees RC
J Immunol; 2002 Apr; 168(7):3512-9. PubMed ID: 11907113
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
Konson A; Ben-Kasus T; Mahajna JA; Danon A; Rimon G; Agbaria R
Cancer Gene Ther; 2004 Dec; 11(12):830-40. PubMed ID: 15359292
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
Liu RB; Rabkin SD
Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
